Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 5, 2012

View Archived Issues

Stem cell gene therapy improves erectile dysfunction in rats

Novel HCV candidate identified by group in Taiwan

Roche Glycart patents novel IL-2 immunoconjugates

Russian group prepares new monoclonal antibodies

Plexxikon discloses novel protein kinase inhibitors

A novel pan-JAK inhibitor shows promise for adjuvant-induced arthritis

Indiana University researchers divulge new peptide phospholipid conjugates

Teduglutide receives European marketing authorization for short bowel syndrome

Novel antibacterial agents presented by Daiichi Sankyo

BioLineRx and Biokine Therapeutics enter licensing agreement for hematological cancers

Enrollment completed in phase III ATX-101 trial for submental fat

GlaxoSmithKline identifies novel DNA gyrase inhibitors for the treatment of tuberculosis

First patient enrolled in phase II AVP-923 trial in Alzheimer's disease

Sarepta Therapeutics receives U.S. government funding for Marburg virus therapy

Zalicus begins first of two phase IIa Z-160 studies in neuropathic pain

ImmusanT begins Nexvax-2 trials in celiac disease

AlloCure begins phase II study in acute kidney injury

BioSante Pharmaceuticals reports phase III safety data for LibiGel

Myrexis returns compounds to EpiCept

Relmada Therapeutics devises extended-release delivery systems for REL-1041

Baxter submits BLA to FDA seeking approval of hemophilia B drug

NIDA to fund phase II methamphetamine addiction trial of MN-166

GSK-961081 demonstrates efficacy as a bronchodilator in a phase II study

FDA approves Pfizer's bosutinib for CML

Medivir acquires preclinical antiviral programs from Novadex

New funding supports Cellerant's development of CLT-008

Dainippon Sumitomo Pharma seeks Chinese approval for amrubicin for SCLC